CDKN2A homozygous deletion is a poor prognostic biomarker in B-cell lymphomas in general and has also been reported to be a common molecular abnormality in the PCNSLs of older patients [53,65]. This evidence concerns the gene CDKN2A and B-cell non-Hodgkin lymphoma.